If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

NEW GLOBAL CONTRACT

4 Jun 2007 07:00

Byotrol PLC04 June 2007 BYOTROL NEW GLOBAL CONTRACT ANNOUNCEMENT The Directors of Byotrol plc (the "Company") are pleased to be able to report anew global contract that has been secured by the Company. The Company has worked in partnership to develop a range of productsincorporating Byotrol(R) technology for Fellowes Inc, a leading global providerof office accessories and business machines. As a global provider, Fellowes has access to a wide range of disinfectanttechnologies and chose Byotrol for its residual efficacy, ultra low toxicityprofile and broadband action against a wide range of micro-organisms. Fellowes is launching the Virashield(TM) range of products containing Byotrolacross Europe with a global launch planned in the near future. The range, whichincludes wipes and hand protection foam, is designed to help combat the spreadof infections in the workplace. Virashield(TM) offers both residual efficacy ofup to seven days coupled with broad spectrum capability against a wide range oforganisms including viruses such as influenza and avian flu and bacteriaincluding E.coli. Research has shown that a typical office desk harbours up to400 times more bacteria than a typical toilet seat and the residual efficacyoffered by the Virashield range containing Byotrol will help office workerscombat this real and growing risk of infection. The Virashield(TM) range has been extensively tested by both Byotrol andFellowes and the tests have proven the product's efficacy for up to seven daysfollowing application. The range can both remove microbes from surfaces in anoffice environment and keep the surface microbially clean for this period oftime. Byotrol plc Chief Executive David McRobbie said, "We are delighted to havesecured our first contract that will make Byotrol available on a global basisand that a company the size of Fellowes chose Byotrol as its worldwide strategicpartner for this key product launch. There is growing awareness thatmicro-organisms are not just an issue in hospitals and specialist environmentsand that effective cleaning regimes have a role in a wider range of settings." Headquartered in Illinois, USA with subsidiaries in Canada, Benelux, France,Germany, Italy, Poland, Spain, UK, China, Singapore, Japan, Korea and Australia,they have an extensive distribution & export network reaching over 100countries. Fellowes employs more than 2,700 people throughout the world andexpects global sales in excess of $700 million this year. Enquiries: Byotrol plc 0161 277 9518Stephen Falder Deputy Chairman Richard Bell 07825 204 110Finance Director Charles Stanley Securities 020 7149 6457Philip Davies McCann Erickson PR 01625 822540Jim Rothnie Rawlings Financial 01756 770376John Rawlings This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Nov 202111:36 amRNSTotal Voting Rights
1st Nov 202111:20 amRNSHolding(s) in Company
28th Oct 202111:40 amRNSExercise of Options & Total Voting Rights
20th Oct 20214:46 pmRNSResult of AGM
1st Oct 20217:00 amRNSSale of Byotrol24 in the Americas
27th Sep 20214:36 pmRNSPosting of Annual Report & Accounts/Notice of AGM
1st Sep 20217:00 amRNSInvestor Presentation
20th Aug 202110:01 amRNSHolding(s) in Company
19th Aug 20217:00 amRNSFinal Results
27th Jul 20217:00 amRNSNotice of Results
21st Jun 20217:00 amRNSAlcohol-free Hand Sanitisers Backed by TIGGR
28th Apr 20219:47 amRNSExercise of Options & Total Voting Rights
27th Apr 20217:00 amRNSHolding(s) in Company
22nd Apr 20212:05 pmRNSSecond Price Monitoring Extn
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNSTrading Update
16th Apr 20214:40 pmRNSHolding(s) in Company
26th Feb 20217:00 amRNSTest Protocol for Testing Anti-Viral Efficacy
21st Jan 202110:30 amRNSExercise of Options & Total Voting Rights
8th Jan 20219:36 amRNSCapital reduction
21st Dec 20208:26 amRNSHolding(s) in Company
7th Dec 20207:00 amRNSInterim Results
13th Nov 202011:30 amRNSResult of AGM
13th Nov 20207:00 amRNSAGM Statement
6th Nov 202011:27 amRNSAnnual General Meeting – update on arrangements
20th Oct 20201:42 pmRNSPosting of circular & notice of AGM
14th Oct 20204:30 pmRNSExercise of Options & Total Voting Rights
13th Oct 202011:09 amRNSPUBLICATION OF AUDITED RESULTS
25th Sep 20207:00 amRNSDirector Dealing
25th Sep 20207:00 amRNSInvestor Presentation
24th Sep 20207:00 amRNSPreliminary Results
7th Sep 20207:00 amRNSGrant Award
27th Aug 20208:07 amRNSHolding(s) in Company
20th Aug 20208:10 amRNSHolding(s) in Company
18th Aug 20205:01 pmRNSHolding(s) in Company
18th Aug 20204:42 pmRNSSecond Price Monitoring Extn
18th Aug 20204:36 pmRNSPrice Monitoring Extension
17th Aug 20209:05 amRNSSecond Price Monitoring Extn
17th Aug 20209:00 amRNSPrice Monitoring Extension
3rd Aug 20207:00 amRNSTrading Update
16th Jul 20202:40 pmRNSHolding(s) in Company
3rd Jul 20207:00 amRNSExercise of Options and Total Voting Rights
29th Jun 20204:29 pmRNSHolding(s) in Company
19th May 202012:08 pmRNSHolding(s) in Company
14th May 20207:00 amRNSLicense Agreements and Update on Trading
27th Apr 20207:30 amRNSTrading Update
22nd Apr 20204:41 pmRNSSecond Price Monitoring Extn
22nd Apr 20204:36 pmRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSHolding(s) in Company
6th Apr 202011:26 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.